[go: up one dir, main page]

AR060039A1 - NEW FORMULATIONS - Google Patents

NEW FORMULATIONS

Info

Publication number
AR060039A1
AR060039A1 ARP070101155A ARP070101155A AR060039A1 AR 060039 A1 AR060039 A1 AR 060039A1 AR P070101155 A ARP070101155 A AR P070101155A AR P070101155 A ARP070101155 A AR P070101155A AR 060039 A1 AR060039 A1 AR 060039A1
Authority
AR
Argentina
Prior art keywords
formulations
formula
biocompatible polymer
independently
biocompatible
Prior art date
Application number
ARP070101155A
Other languages
Spanish (es)
Original Assignee
3M Innovative Properties Co
Glaxo Wellcome Mfg Pte Ltd
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3M Innovative Properties Co, Glaxo Wellcome Mfg Pte Ltd, Glaxo Group Ltd filed Critical 3M Innovative Properties Co
Publication of AR060039A1 publication Critical patent/AR060039A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Formulaciones farmacéuticas en aerosol, procesos para su preparacion, su uso en terapia, inhaladores de dosificacion que contienen dichas formulaciones y el uso de polímeros biocompatibles para reducir la variabilidad en la uniformidad de contenido y/o proporcionar una fraccion de partículas finas mejorada en dichas formulaciones. Reivindicacion 1: Una formulacion farmacéuticamente en aerosol que contiene: (i) una cantidad terapéuticamente efectiva de medicamento en partículas de la formula (1) o un solvato de esta; (ii) un propulsor seleccionado del grupo que consiste en 1,1,1,2-tetrafluoroetano o 1,1,1,2,3,3,3,-heptafluoro-n-propano o mezclas de estos; y (iii) un polímero biocompatible que comprende uno o más compuestos de la formula (2). Donde n y m representan independientemente un numero entero de al menos uno y el valor de promedio independiente de n y m en el polímero biocompatible está entre 6 y 25; y cada unidad de la formula (3) se encuentra independientemente en el configuracion D o L.Pharmaceutical aerosol formulations, processes for their preparation, their use in therapy, dosing inhalers containing said formulations and the use of biocompatible polymers to reduce variability in content uniformity and / or provide an improved fine particle fraction in said formulations . Claim 1: A pharmaceutically aerosol formulation containing: (i) a therapeutically effective amount of particulate medicament of the formula (1) or a solvate thereof; (ii) a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3, -heptafluoro-n-propane or mixtures thereof; and (iii) a biocompatible polymer comprising one or more compounds of the formula (2). Where n and m independently represent an integer of at least one and the independent average value of n and m in the biocompatible polymer is between 6 and 25; and each unit of the formula (3) is independently in the D or L configuration.

ARP070101155A 2006-03-22 2007-03-21 NEW FORMULATIONS AR060039A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
AR060039A1 true AR060039A1 (en) 2008-05-21

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101155A AR060039A1 (en) 2006-03-22 2007-03-21 NEW FORMULATIONS

Country Status (18)

Country Link
EP (1) EP2012797A2 (en)
JP (1) JP2009530419A (en)
KR (1) KR20080110854A (en)
CN (1) CN101415428A (en)
AR (1) AR060039A1 (en)
AU (1) AU2007226899A1 (en)
BR (1) BRPI0708798A2 (en)
CA (1) CA2646236A1 (en)
CR (1) CR10261A (en)
EA (1) EA200801854A1 (en)
IL (1) IL193723A0 (en)
MA (1) MA30328B1 (en)
MX (1) MX2008011967A (en)
NO (1) NO20083760L (en)
PE (1) PE20080124A1 (en)
TW (1) TW200803870A (en)
WO (1) WO2007109698A2 (en)
ZA (1) ZA200807682B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2994042T3 (en) 2009-02-26 2025-01-16 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
CN1294141C (en) * 2000-08-05 2007-01-10 葛兰素集团有限公司 6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative

Also Published As

Publication number Publication date
WO2007109698A2 (en) 2007-09-27
MX2008011967A (en) 2009-01-14
CA2646236A1 (en) 2007-09-27
WO2007109698A3 (en) 2008-12-18
CN101415428A (en) 2009-04-22
TW200803870A (en) 2008-01-16
IL193723A0 (en) 2009-08-03
CR10261A (en) 2008-11-26
EP2012797A2 (en) 2009-01-14
ZA200807682B (en) 2009-11-25
EA200801854A1 (en) 2009-04-28
JP2009530419A (en) 2009-08-27
NO20083760L (en) 2008-12-17
MA30328B1 (en) 2009-04-01
PE20080124A1 (en) 2008-04-21
KR20080110854A (en) 2008-12-19
AU2007226899A1 (en) 2007-09-27
BRPI0708798A2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
BR9916865A (en) Aerosol pharmaceutical composition containing hfa 227 and hfa 134a
BR0303348A (en) Aerosol formulations for pulmonary drug delivery to produce systemic effect
WO2004108162A3 (en) Controlled release pharmaceutical composition
BRPI0412211A (en) controlled release compositions
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
NZ588913A (en) Liver cancer drug
PE20080765A1 (en) PHARMACEUTICAL DOSAGE FORMS
BRPI0414907A (en) injectable, oral or topical sustained release pharmaceutical formulations
DE60104399D1 (en) POWDER FORMULATION FOR INHALATION
NO20062504L (en) Compositions and dosage forms for improved absorption
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR045076A1 (en) COMPOSITION OF FILM THAT DISSOLVES ORALALLY, MULTICOMPONENT FILM THAT DISSOLVES ORALALLY, USE OF THE FILM COMPOSITION AND THE FILM THAT ORALLY DISSOLVES TO PREPARE A MEDICINAL PRODUCT, FORM OF ORAL DOSAGE AND PROCEDURE FOR PREPARATION OF COMPOSITION
AR018891A1 (en) PRESSURIZED INHALERS OF DOSAGE MEASUREMENT AND PHARMACEUTICAL FORMULATIONS IN AEROSOL
RS52940B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
AR066313A2 (en) A CONTROLLED RELEASE FORMATION OF GALANTAMINE, A PHARMACEUTICAL FORM OF DOSAGE, A PROCESS FOR THE PREPARATION OF SUCH FORMULATION, AND THE USE OF SUCH FORMULATION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
UY29905A1 (en) PHARMACEUTICAL FORMULATION OF ORAL ABSORPTION AND ITS METHOD OF ADMINISTRATION
ATE389389T1 (en) MULTIPLE COATED PHARMACEUTICAL DOSAGE FORM
TNSN02039A1 (en) RECONSTITUTABLE PARENTERAL COMPOSITION
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
MX2007006212A (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form.
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
BRPI0411165A (en) pharmaceutical composition, dosage unit form and methods for preparing its use
MX2010003923A (en) Pharmaceutical formulation of valsartan.
UY29085A1 (en) PIRIMIDINE DERIVATIVES 4-SULFONAMID SUBSTITUTED, INTERMEDIATE COMPOUNDS FOR PREPARATION, PREPARATION PROCEDURES, MEDICINAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal